Kornimate/medical-research-clean huggingface dataset:
the role of theophylline plus low-dose formoterol-budesonide in treatment of bronchiectasis

Conditions: Bronchiectasis

Summary: the purpose of this study is to examine the efficacy and safety of 24 weeks treatment with theophylline plus low-dose formoterol-budesonide in subjects with bronchiectasis.

non-cystic fibrosis bronchiectasis is an orphan disease caused by the pathogenic vicious circle including infection, inflammation and airway repair. today's principle of treatment is to break the cycle of inflammation and infection. nowadays, most clinical trials are anti-infective treatment by antibiotics trying to break this cycle by reducing the bacterial load, which may cause bacterial resistance. there were still some anti-inflammation trials by using inhaled corticosteroids(ics). tsang and martínez-garcía showed that inhaled corticosteroids reduced il-1,il-8 levels and sputum inflammation cells, and improved sputum volume as well as quality of life, though the corticosteroid must be high dose or medium dose combined with long-acting ß2 adrenergic agonists. as described in asthma and chronic obstructive pulmonary disease(copd), theophylline can improve the activity of histone deacetylase (hdac) and then enhanced the anti-inflammatory effect of steroids. we hypothesis that theophylline may have the same effect in subjects with bronchiectasis. theophylline plus inhaled low-dose formoterol-budesonide may improve quality of life and reduce airway inflammation.

Eligibility criteria:
inclusion criteria: * patients between 18-70 years old with non-cystic fibrosis(cf) bronchiectasis, free from acute exacerbations for at least 3 months.stable phase of the disease. exclusion criteria: * patients with a cigarette smoking history of more than 10 packs-year. patients with copd. patients with traction bronchiectasis due to advanced fibrosis. patients with known intolerance for theophylline. patients with asthma. patients with other disease disturbing outcomes of the trials. patients without consent.

Keywords: bronchiectasis theophylline therapeutic uses hdac hat random placebo study ics(inhaled corticosteroid) corticosteroid inhaled corticosteroid
advanced carbohydrate counting and automated bolus calculation

Conditions: Type 1 Diabetes

Summary: the investigators hypothesize, that non-optimally treated carbohydrate counting-naïve patients with type 1 diabetes can achieve better metabolic control by counting carbohydrates, and that the metabolic control can be further improved with concurrent use of accu-chek aviva expert. additionally, the investigators propose that carbohydrate counting will lead to better quality of life as a result of fewer restrictions when eating and less variation in blood glucose. finally the investigators hypothesize that the use of accu-chek aviva expert will lead to fewer hypoglycemic episodes.


Eligibility criteria:
inclusion criteria: * patients with type 1 diabetes * age \>18 years * diabetes duration more than 12 months * multiple daily injections therapy (fast acting analog for meals; long acting analog as basal) * hba1c between 8.0% and 11.3% exclusion criteria: * present or former practice of carbohydrate counting * gastroparesis * pregnancy or nursing

Keywords: automated bolus calculator (abc) advanced carbohydrate counting (acc) patient empowerment
abdominal pain disorders functional in children: impact of hypno-analgesia on the autonomic balance

Conditions: Child; Abdominal Pain

Summary: abdominal pain disorders functional (including functional dyspepsia, irritable bowel syndrome, abdominal migraine, functional abdominal pain) is a very common disease in the pediatric population, where classical medical treatment does not always prove effective. this clinical entity has an impact on the individual physiological balance particularly on the autonomic regulation. studies concerning adults with irritable bowel syndrome, showed significant changes in heart rate variability indices (hrv: heart rate variability). the study of time and frequency domain analysis of hrv allows noninvasive and reproducible assessment of the cardiac sympathetic and parasympathetic tone. the investigators hypothesize that the sympathovagal balance could be altered in children in case of prolonged nociceptive stress as the investigators find it especially in irritable bowel syndrome and functional abdominal pain. in recent years, the control of pediatric pain experienced considerable growth through hypnosis techniques and several studies have shown analgesic efficacy with a beneficial effect in terms of quality of life in children. our study aims to assess the impact of the hypno-analgesia treatment of abdominal pain disorders functional on sympathovagal balance. the investigators propose to realize in 7 to 18 years old children with abdominal pain disorders functional a single center prospective study to highlight after a standardized hypnosis program, changes in the time and frequency domain indices of heart rate variability and clinical or quality of life parameters. the primary endpoint will be the high frequency hf indice. secondary endpoints will be the other indices of hrv (ptot, vlf, lf, ratio lf / hf, sdnn, sdann, pnn50, rmssd), the quality of life questionnaire values (pedsql ™ 4.0) a pain scale and the composite score of francis.


Eligibility criteria:
inclusion criteria: * parents affiliates or entitled to a social security scheme * consent form signed by the holder of parental authority exclusion criteria: * child with pathologies reaching the central nervous system or the brain stem. * children with a severe pathology of cardio-respiratory or heart being referred to treatment. * children requiring emergency surgery or trauma or septic or inflammatory context. * children with psychiatric disorders or mental retardation proven. * children who have already used the earlier hypnosis. * children not speaking french language.

Keywords: nervous system hypnosis electrocardiography, ambulatory abdominal pain disorders functional
modalities of renal replacement therapy in pediatric acute kidney injury

Conditions: Kidney Failure, Acute

Summary: limited prospective data is available to compare morbidity and mortality between renal replacement modalities in pediatric acute renal failure. in the absence of clear standard of care, the choice of the extra renal replacement therapy modality is subject to clinical judgement, practical aspects, and costs. this study will supply important data about usual modalities of pediatric acute extra renal replacement therapy and their impact on patient outcome and renal recovery. an obvious next step will be to conduct a randomized controlled trial comparing the different strategies.

in children, there are limited data on extra renal replacement therapy. pediatric studies are often retrospective, or often limited to specific disease processes or specific extra renal therapy. the lack of large studies including different usual modalities in pediatrics limits any formal recommendation on use in relation to patient outcomes, including renal recovery and mortality. some of the issues that need consideration are the choice of dialysis modality (including intermittent hemodialysis, continuous renal replacement therapies, and peritoneal dialysis), the indications for and timing of dialysis intervention, the dose of dialysis and their effects on outcomes from acute kidney injury in children. this study will supply important data about pediatric acute extra renal replacement therapy, including the epidemiology of pediatric acute kidney injury leading to extra renal replacement therapy, the variety of the treatment modalities, and their effects on the course of the disease.

Eligibility criteria:
inclusion criteria: * age \< 18 years, including the newborn ; * acute kidney injury as defined by prifle classification requiring extra renal replacement therapy, whatever is the method. exclusion criteria: * treatment by extra renal replacement therapy for terminal renal failure; * history of renal transplantation; * extra renal replacement therapy for an inborn errors of metabolism without acute renal failure; * extra renal replacement therapy in the context of a drug intoxication without acute renal failure; * treatment by technique in mars (molecular adsorbent recirculating system); * modified ultrafiltration during surgery.

Keywords: pediatric acute renal failure acute extra renal replacement therapy intermittent hemodialysis continuous renal replacement therapies peritoneal dialysis
plasma proteomics study of end-stage liver disease patients based on olink technology

Conditions: HBV Related Acute-on-chronic Liver Failure

Summary: exploring early biomarkers of hepatitis b virus-related acute-on-chronic liver failure using olink proteomics

the rationale for this study is that, with the changing epidemiology of liver diseases, traditional diagnostic methods are no longer sufficient to meet clinical needs. olink technology, however, offers the potential to discover novel biomarkers. by comparing the plasma proteomic profiles of patients with cirrhosis and liver failure, we aim to identify clinically significant markers. this not only has the potential to enhance early diagnostic capabilities but also provides an important basis for personalized treatment.

Eligibility criteria:
inclusion criteria: * hbv-lc patients were diagnosed based on previous liver biopsy results or clinical evidence and laboratory tests of previous decompensation for more than three months, including ascites, gastrointestinal bleeding, infection, hepatic encephalopathy, or a combination of these symptoms, endoscopic examination (esophageal and gastric varices), and radiological imaging of portal hypertension and/or liver nodules. the inclusion criteria for hbv-achd patients in this study were based on patients with chronic stable decompensated cirrhosis who experienced an acute decompensation within three months. the reference criteria for acute decompensation in the hbv-achd group were as follows: patients with previously diagnosed decompensated cirrhosis presenting with a high level of jaundice (total bilirubin ≥5 mg/dl) hbv-aclf was categorized into three grades based on the severity of the condition. the inclusion criteria for hbv-aclf-1 were as follows: patients presenting with liver failure alone with an international normalized ratio (inr) ≥1.5 and/or kidney dysfunction and/or hepatic encephalopathy (he) grade i or ii. hbv-aclf-2 was defined by dual-organ system failure, while hbv-aclf-3 was characterized by failure involving three or more organ systems. exclusion criteria: * associated with other types of hepatitis virus infection or hiv infection, alcoholic liver disease, autoimmune liver disease, drug-induced liver injury; ② suffering from primary liver cancer or severe heart, digestive, lung, kidney, neurological and psychiatric diseases; ③ patients with incomplete data and patients unable to participate in the experiment.
rollover study for zerit (stavudine) er studies (-096, -099)

Conditions: HIV Infections; AIDS

Summary: the purpose of this study is to compare long-term safety and tolerability of stavudine (d4t) extended release (er) versus conventional (immediate release \[ir\]) formulations, each in combination with lamivudine (3tc) and efavirenz (efv) in subjects who have completed bristol-myers squibb (bms) studies ai455-096 and ai455-099.


Eligibility criteria:
inclusion criteria: * completed d4t studies ai455-096 or ai455-099 * have demonstrated compliance with the study medication and treatment visits * provide written informed consent * agree to use a barrier method of birth control (such as condoms) during the study * have a negative pregnancy test within 72 hours prior to start of study medication exclusion criteria: * are pregnant or breast-feeding * need to take certain medications that have systemic myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic or cytotoxic potential * have active alcohol or substance abuse which may prevent compliance or increase risk of developing pancreatitis * have certain other conditions or prior treatments that might interfere with study continuation * need to take certain medications that should not be taken with efv

Keywords: antivirals hiv
modification in cortical activation in pseudophakic patients with visual difficulties after a multifocal implantation

Conditions: Vision Disorders

Summary: this study will highlight differences in cortical activation between asymptomatic and symptomatic patients.


Eligibility criteria:
inclusion criteria: * cataract surgery with an bilateral multifocal lens implant restor symptomatic patients : * symptomatic bilateral visual difficulties for 3 months or more after the intervention which impact the daily activity asymptomatic patients : * no visual complaint for 3 months or more after the intervention exclusion criteria: * patients with ophthalmology disorders * contra indication for fmri

Keywords: functional magnetic resonance imaging lens implantation pseudophakia
problematic use of the internet in child and adolescent psychiatry

Conditions: Substance Use Disorders

Summary: pathological internet use is a blanket term for problematic behavior types (e.g. uncontrolled gaming, cyber pornography, cyber mobbing and excessive use of social media): all perpetrated through the internet. there is little documentation or research on interdependencies/interplay between problematic internet and/or media use and child-adolescent disturbances. very few clinical examples of syndromes like attention deficiency/hyperactivity (adhs), anxiety disorder or affective disturbances associated with pathological media/internet use, or gaming, are found in literature.


Eligibility criteria:
inclusion criteria: * male and female patients ages from 8 - 18 years * all study participants or their legal representative have given written permission for their experiences to be documented in the study. exclusion criteria: * inability to understand explanations and the questionnaire, whether linguistic or cognitative
a user study with vernivia® for bacterial vaginosis.

Conditions: Bacterial Vaginoses

Summary: this is an open user study to evaluate d005 vagnial mousse with regards to user-friendliness, and measure time from start of treatment to symptom relief and measure the clarity of instructional material. the study will be conducted at seven sites in sweden, the study population will consist of up to 100 female subjects.


Eligibility criteria:
inclusion criteria: * age 16 - 49 years informed consent to take part in the study bacterial vaginosis (based on self-assessment or diagnosed by a doctor or midwife) access to a smartphone exclusion criteria: * symptoms of vaginal candida infection and/or pregnancy
the acute effects of coffee on glucose metabolism

Conditions: Type 2 Diabetes

Summary: the purpose of this study was to determine the acute effects of decaffeinated coffee, caffeinated coffee and caffeine on glucose metabolism in humans


Eligibility criteria:
inclusion criteria: * healthy young males * nonsmokers * moderate alcohol users exclusion criteria: * not on any medications that could alter glucose metabolism * no history of blood disorders

Keywords: coffee caffeine glucose metabolism insulin sensitivity diabetes
linkage analysis in interstitial cystitis

Conditions: Prostatitis; Cystitis, Interstitial; Urinary Bladder, Overactive; Chronic Pelvic Pain Syndrome; Painful Bladder Syndrome

Summary: urologic pelvic pain syndrome (ucpps), variably termed painful bladder syndrome/interstitial cystitis (pbs/ic) in females and chronic prostatitis/chronic pelvic pain syndrome in men (cp/cpps), is a chronic, debilitating clinical syndrome presenting as severe pelvic pain with extreme urinary urgency and frequency in the absence of any known cause. the etiologic mechanisms underlying ucpps are unknown, but recurrence, risks to siblings of affected individuals, concordance among monozygotic twins, and our own preliminary studies indicate a strong genetic contribution to the cause of ucpps. the overall goal of this proposal is use novel approaches to understand the basis of ucpps, to identify candidate genes containing mutations that result in ucpps and determine how the different encoded proteins of these genes interact with one another in a common biological pathway. ultimately, understanding how mutations in at least five different genes yield the symptoms of ucpps should lead to improved diagnosis and possible therapies.


Eligibility criteria:
inclusion criteria: * have symptoms for at least 3 months within the preceding 6 months: * pain in the pelvic area * urinary frequency and/or * urinary urgency and/or * sexual dysfunction (erectile dysfunction) * have cp/cpps, ic, pbs, or bfs * be willing to provide a saliva and urine sample * agree to complete several brief questionnaires * family of someone with cp/cpps, pbs, ic or bfs * live in the usa or canada exclusion criteria: * major structural/anatomical urinary tract abnormalities * underlying inborn or congenital conditions

Keywords: prostatitis cystitis, interstitial urinary bladder, overactive chronic pelvic pain syndrome painful bladder syndrome urgency frequency
racial variation in response to music interventions for people with alzheimer's dementia

Conditions: Alzheimer Disease

Summary: this project will study the efficacy of a personalized receptive music intervention on neuropsychiatric symptoms and general cognitive function in patients with mild and moderate alzheimer's disease (ad) by race.

music interventions have become a popular treatment option to be used alongside medicinal treatment for many chronic conditions including alzheimer's disease. healthcare providers and researchers have found that when patients who have chronic conditions engage with music that is patients' preference or most familiar to patients, the patients display positive changes in mood regulation and thinking overall. the investigators are trying to understand to what extent these music interventions could be useful for patients with alzheimer's disease and for which populations the intervention is more effective for. to do this, the investigators are looking to recruit participants with a diagnosis of alzheimer's disease to complete a four (4) week personalized music intervention where patients listen to a one-hour playlist created from patients' described preferences and songs.

Eligibility criteria:
inclusion criteria: * diagnosis of alzheimer's disease * english speaking exclusion criteria: * deaf or hard of hearing
efficacy of pet/mri in detecting metastatic disease in endometrial cancer

Conditions: Endometrial Cancer

Summary: the purpose of this study is to evaluate the ability of pet/mri (positron emission tomography/magnetic resonance imaging) to give physicians preoperative information about specific sites in the body that the endometrial cancer may be present. if the pet/mri is accurate and successful in providing this information, then women in the future may be able to have less extensive surgery for their endometrial cancer after evaluation with pet/mri.

pet/mri has recently become available at the institution and reports of its sensitivity, specificity, npv (negative predictive value) , ppv (positive predictive value), and accuracy in endometrial cancer are not found in the literature to date, to the best of the investigator's knowledge. the ge pet/mri recently obtained here at mayo, rochester has the potential to improve the sensitivity of detection of metastatic disease, compared to other imaging modalities, because of its superior pet technology and updated q clear software. for these reasons it is reasonable to expect improved sensitivity to detect metastatic disease in endometrial cancer, possibly proving pet/mri to be a superior modality for preoperative screening and potentially allowing for less morbid surgical management for patients with high risk endometrial cancer.

Eligibility criteria:
inclusion criteria: * biopsy-proven high-risk endometrial cancer (type 2 or grade 3 endometrioid histology) * bmi of at least 18.5 kg/m2 and less than 35 kg/m2 or axial diameter less than 25 cm * patients who pass standard clinical mri screening procedures * receiving preoperative clinical evaluation at mayo clinic, rochester, mn * undergoing surgical staging and/or debulking at mayo clinic in rochester, mn exclusion criteria: * allergy to fdg or gadolinium * contraindication to mri scanning (extreme claustrophobia preventing pet/mri completion, patients who are unable to lay quietly for an additional 60 minutes of imaging * known kidney disease or poor renal function * pregnant

Keywords: magnetic resonance imaging
change of dual antiplatelet therapy in patients with acute coronary syndrome

Conditions: Acute Coronary Syndrome; Percutaneous Coronary Intervention; Drug-Eluting Stents

Summary: acute coronary syndrome (acs) guidelines have been changed, favoring dual antiplatelet therapy (dapt) with the more potent p2y12 inhibitor ticagrelor over clopidogrel (besides aspirin). this change is based on studies that showed benefits of ticagrelor. however, study participants were only partly treated by percutaneous coronary intervention (pci). in patients who were treated by pci, this was generally performed using of bare metal or first-generation drug-eluting stents (des). change dapt is an investigator-initiated, prospective, single centre registry, in which we evaluate the impact of the guideline suggested change in the primary dapt regimen (from clopidogrel to ticagrelor) on 1-year clinical outcome in acs patients treated by pci with newer-generation des in the thoraxcentrum twente.


Eligibility criteria:
inclusion criteria: * presentation with acute coronary syndrome (acs) * treated with newer-generation drug-eluting stent (des) in coronary artery or bypass graft lesion exclusion criteria: * known pregnancy * life expectancy less than one year * planned elective surgery requiring interruption of dapt in the first 6 months * known intolerance to components of the des available * indication for oral anticoagulation at baseline

Keywords: acute coronary syndrome percutaneous coronary intervention drug-eluting stents platelet aggregation inhibitors ticagrelor clopidogrel purinergic p2y receptor antagonists
icbtg in routine care

Conditions: Problem Gambling; Gambling Disorder

Summary: problem gambling (pg) is a major public health concern worldwide. as awareness of pg has risen, treatment demand is increasing, and internet interventions is a promising alternative for providing fast, evidence-based treatment at scale, to a low cost. this article presents the protocol of an open label, uncontrolled pilot and feasibility trial of a novel internet-delivered cognitive behavioral treatment, conducted in regular addiction care with adult treatment-seeking patients (max n=25) with problematic gambling. weekly measures of gambling symptoms and gambling will serve as outcome measures. study results will further guide the development of the intervention and its implementation into regular addiction care.


Eligibility criteria:
inclusion criteria: * being at least 18 years old * living in sweden * being able to read and write swedish. * having a total score of \>= 3 on the problem gambling severity index (pgsi; ferris \& wynne, 2001) * having the ability to work with online treatment material by themselves (with support from a therapist) exclusion criteria: * fulfilling criteria for ongoing manic episode * currently undergoing a parallel cbt treatment for gambling disorder or problem gambling.

Keywords: internet intervention gambling disorder cognitive-behavioral therapy psychiatric comorbidity regular addiction care problem gambling